WiCell Expands Stem Cell Collection with Six New LQT Interval Cardiac Trait Cell Lines
PRESS RELEASE
20 March, 2025
Madison, WI—WiCell, an organization dedicated to supporting research and the advancement of novel therapies through innovative technologies and services, is pleased to announce the addition of six new NHLBI Next Gen - QT Interval and ECG Cardiac Traits cell lines to its growing stem cell repository. With these new additions, WiCell's catalog now offers 1,542 stem cell lines to further support stem cell research and the development of the next generation of therapeutics.
The new CRISPR-edited Long QT (LQT) iPSC variant and control cell lines were developed by Dr. Kelly Frazer at the University of California San Diego, are part of the National Heart, Lung, and Blood Institute (NHLBI) Next Generation Genetic Association Studies (Next Gen) Program, which provides researchers with genetically diverse and well-characterized cell lines to study cardiac diseases. These valuable resources enable researchers to investigate the genetic basis of cardiovascular conditions, providing new opportunities for drug discovery and personalized medicine.
“As the demand for diverse, high-quality stem cell lines grows, we’re proud to expand our collection to better serve the scientific community,” said Robert Drape, CEO of WiCell. “This set of isogenic iPSC lines edited for LQT-causal variants and control lines are invaluable tools for studying Long QT Syndrome and offer significant potential for drug screening workflows and gene therapy studies.”
Explore the full collection on the WiCell NHLBI Next Gen Frazer collections page.
About WiCell (wicell.org)
Headquartered in Madison, Wisconsin, WiCell is a supporting organization of the University of Wisconsin–Madison, a world leader in the area of human pluripotent stem cell research. Established in 1999 to advance stem cell technologies, our mission extends beyond providing high-quality stem cell lines and characterization services. We are dedicated to advancing regenerative medicine and cell and gene therapy globally. Through promoting best practices in cell banking and characterization, we aim to support groundbreaking research and clinical applications. Our efforts—rooted in a commitment to quality, innovation, and collaboration—underscore our desire to support the scientific community as your lab partner.
Madison, WI—WiCell, an organization dedicated to supporting research and the advancement of novel therapies through innovative technologies and services, is pleased to announce the addition of six new NHLBI Next Gen - QT Interval and ECG Cardiac Traits cell lines to its growing stem cell repository. With these new additions, WiCell's catalog now offers 1,542 stem cell lines to further support stem cell research and the development of the next generation of therapeutics.
The new CRISPR-edited Long QT (LQT) iPSC variant and control cell lines were developed by Dr. Kelly Frazer at the University of California San Diego, are part of the National Heart, Lung, and Blood Institute (NHLBI) Next Generation Genetic Association Studies (Next Gen) Program, which provides researchers with genetically diverse and well-characterized cell lines to study cardiac diseases. These valuable resources enable researchers to investigate the genetic basis of cardiovascular conditions, providing new opportunities for drug discovery and personalized medicine.
“As the demand for diverse, high-quality stem cell lines grows, we’re proud to expand our collection to better serve the scientific community,” said Robert Drape, CEO of WiCell. “This set of isogenic iPSC lines edited for LQT-causal variants and control lines are invaluable tools for studying Long QT Syndrome and offer significant potential for drug screening workflows and gene therapy studies.”
Explore the full collection on the WiCell NHLBI Next Gen Frazer collections page.
About WiCell (wicell.org)
Headquartered in Madison, Wisconsin, WiCell is a supporting organization of the University of Wisconsin–Madison, a world leader in the area of human pluripotent stem cell research. Established in 1999 to advance stem cell technologies, our mission extends beyond providing high-quality stem cell lines and characterization services. We are dedicated to advancing regenerative medicine and cell and gene therapy globally. Through promoting best practices in cell banking and characterization, we aim to support groundbreaking research and clinical applications. Our efforts—rooted in a commitment to quality, innovation, and collaboration—underscore our desire to support the scientific community as your lab partner.
